StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
MTEX

Mannatech, Incorporated

MTEX Nasdaq Medicinal Chemicals & Botanical Products EDGAR ↗
$7.60
-0.23 -2.94%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$14.7M
Revenue (TTM) ⓘ
$107M
Net income (TTM) ⓘ
-$7.39M
EPS (TTM) ⓘ
$-3.91
P/E ratio ⓘ
—
Dividend yield ⓘ
2.63%
Free cash flow ⓘ
-$4.32M
Cash ⓘ
$6.03M
Total assets ⓘ
$27.5M
Gross margin ⓘ
76.1%
52-week range ⓘ
$3.80 – $12.45

AI briefing

from the latest 10-K, 10-Q and 8-K events

Mannatech is a global network-marketing wellness company selling proprietary nutritional supplements, skin care and weight-management products through roughly 116,000 independent associates and preferred customers across three regions.

What they do

Mannatech develops and sells proprietary nutritional supplements, skin care and anti-aging products, and weight-management products, operating as a single reporting segment in the nutritional supplement industry. Products are sold principally through network marketing via independent associates and preferred customers, with approximately 114,000 active associate and preferred customer positions as of December 31, 2025 and approximately 116,000 as of June 30, 2026. It sells in the Americas (U.S., Canada, Mexico), EMEA (14 listed countries), and Asia/Pacific (Australia, Japan, New Zealand, Republic of Korea, Singapore, Thailand, Taiwan, Hong Kong, China), and ships to several additional European countries. Mainland China operations run through subsidiary Meitai under a cross-border e-commerce model that is not direct selling or multi-level marketing.

Revenue drivers

  • Nutritional supplements (core products) — Proprietary nutritional supplements sold through independent associates and preferred customers are the center of the single reporting segment; the company describes itself as operating in the nutritional supplement industry.
  • Skin care and anti-aging products — Sold through the same network-marketing channel alongside supplements; no separate revenue figure is broken out in the excerpts provided.
  • Weight-management and fitness products — The third stated product category sold through the same associate network; no separate revenue figure is disclosed in the excerpts.
  • Meitai cross-border e-commerce (China) — Meitai sells overseas-manufactured Mannatech products to Chinese consumers via its website for personal use, with a customer referral rewards program; it cannot operate as direct selling or multi-level marketing in China.

Recent performance

Second quarter 2026 net sales were $26.7 million, up $1.0 million from the prior-year quarter, or up 5.1% on a constant-dollar basis with foreign exchange reducing GAAP sales by $0.3 million. Gross margin rose to 76.9% from 73.6%, and selling and administrative expenses fell $1.8 million, or 16.7%, to $9.0 million (33.7% of net sales versus 42.0%). Income from operations was $1.0 million versus a $1.4 million operating loss a year earlier, and net income was $1.0 million, or $0.53 per diluted share, compared to a net loss of $4.3 million, or $2.27 per diluted share. Full-year 2025 revenue was $108.0 million with a net loss of $15.2 million and negative operating cash flow of $3.0 million. Cash and equivalents were $6.0 million at June 30, 2026, down from $6.2 million at December 31, 2025.

Strategy

The company continues to rely on network marketing as its primary distribution method, describing it as cost-effective and responsive relative to conventional marketing. It points to controlled international expansion, research and development of proprietary products, and its China cross-border e-commerce subsidiary Meitai, which operates outside direct selling. Management cited cost controls in the second quarter, with selling and administrative expenses down 16.7% and operating income positive. The company also flagged that changes in trade policies, including tariffs, could affect its cost structure and profitability and that its ability to mitigate those costs may be limited by supply chain constraints. No new capital projects, acquisitions or dividend plans are described in the provided excerpts.

Risks

  • Associate recruitment and retention — The company states its future success depends largely on attracting and retaining a large active base of independent associates and preferred customers, and it cannot assure that associate counts will be maintained or grow.
  • Declining revenue and profitability — Revenue fell from $159.8 million in 2021 to $108.0 million in 2025, with a $15.2 million net loss and negative $3.0 million operating cash flow in 2025.
  • Negative shareholders' equity and liquidity — At June 30, 2026 the company reported total liabilities of $32.4 million against total assets of $27.5 million, shareholders' equity of negative $5.0 million, and $6.0 million of cash.
  • Tariffs, trade policy, and foreign exchange — Management stated changes in trade policies including tariffs could affect the cost structure and profitability, with mitigation limited by operational and supply chain constraints, and foreign exchange reduced second-quarter GAAP net sales by $0.3 million.

Outlook

Management did not provide numeric guidance in the earnings release; it highlighted improved second-quarter net sales, gross margin, and lower selling and administrative expenses. The company cautioned that changes in trade policies, including tariffs, could affect its cost structure and profitability and that its ability to mitigate them may be limited, especially in the short term. Filings also list among forward-looking items management's expectation that existing cash flows will be adequate to fund future operational needs and its ability to curtail operating expenditures.

Recent SEC filings

40 most recent
Annual, quarterly & current reports